Celularity Past Earnings Performance
Past criteria checks 0/6
Celularity has been growing earnings at an average annual rate of 21.3%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 20.5% per year.
Key information
21.3%
Earnings growth rate
77.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 20.5% |
| Return on equity | -405.7% |
| Net Margin | -264.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Celularity Inc. (NASDAQ:CELU) Held Back By Insufficient Growth Even After Shares Climb 80%
Feb 14
Celularity appoints Adrian Kilcoyne as chief medical officer
Oct 03Celularity falls after announcing fund raising deal
Sep 15Celularity falls 10% on deal for $150M common stock offering
Sep 08Celularity begins phase 1/2a trial for cell therapy CYNK-101 to treat cancers
Jul 27Revenue & Expenses Breakdown
How Celularity makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 43 | -113 | 54 | 15 |
| 31 Mar 24 | 34 | -154 | 51 | 19 |
| 31 Dec 23 | 23 | -196 | 51 | 30 |
| 30 Sep 23 | 15 | -181 | 57 | 42 |
| 30 Jun 23 | 15 | -83 | 61 | 57 |
| 31 Mar 23 | 16 | 13 | 63 | 74 |
| 31 Dec 22 | 18 | 14 | 66 | 78 |
| 30 Sep 22 | 19 | -14 | 51 | 89 |
| 30 Jun 22 | 25 | 31 | 58 | 92 |
| 31 Mar 22 | 25 | -81 | 71 | 90 |
| 31 Dec 21 | 21 | -100 | 62 | 85 |
| 30 Sep 21 | 20 | -92 | 64 | 78 |
| 30 Jun 21 | 12 | -188 | 51 | 65 |
| 31 Mar 21 | 13 | -260 | 30 | 58 |
| 31 Dec 20 | 14 | -208 | 31 | 53 |
| 30 Sep 20 | 16 | -234 | 35 | 52 |
| 31 Dec 19 | 21 | -212 | 42 | 46 |
| 31 Dec 18 | 18 | -13 | 50 | 29 |
Quality Earnings: CELU is currently unprofitable.
Growing Profit Margin: CELU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CELU is unprofitable, but has reduced losses over the past 5 years at a rate of 21.3% per year.
Accelerating Growth: Unable to compare CELU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CELU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CELU has a negative Return on Equity (-405.7%), as it is currently unprofitable.